Literature DB >> 1444877

Effect of long-term therapy on the pharmacodynamics of levodopa. Relation to on-off phenomenon.

J G Nutt1, W R Woodward, J H Carter, S T Gancher.   

Abstract

To determine how the response to levodopa is altered by long-term therapy, we examined the dose response to 2-hour infusions of levodopa in three groups of parkinsonian patients: those who were previously untreated, those who exhibited stable responses, and those who exhibited fluctuating responses to levodopa therapy, using tapping speed as an index of bradykinesia. The baseline tapping speed was greater in the patients with stable responses than in the untreated patients, probably representing a "long-duration response" to levodopa therapy. A "short-duration response," indicated by an increase in tapping speed lasting hours, was observed in most patients in all groups. The onset of the short-duration effect was more rapid and the incremental increase in tapping speed was twice as large in the patients with fluctuating responses compared with the untreated patients and patients with stable responses. The duration of the short-duration effect was greatest in the untreated group but did not differ between the groups with stable and fluctuating responses. Dyskinesia was not observed in any of the de novo patients but was observed in three of 12 patients with stable responses and eight of nine patients with fluctuating responses to levodopa therapy. Dyskinesia appeared before or with the antiparkinsonian effects in patients with stable responses, giving no indication of a higher threshold for dyskinesia in these patients compared with those with fluctuating responses. The plasma half-life clearance, volume of distribution, and maximum plasma concentrations of levodopa did not differ among groups.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1444877     DOI: 10.1001/archneur.1992.00530350037016

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  29 in total

1.  Vesicular monoamine transporter-2 and aromatic L-amino acid decarboxylase enhance dopamine delivery after L-3, 4-dihydroxyphenylalanine administration in Parkinsonian rats.

Authors:  W Y Lee; J W Chang; N L Nemeth; U J Kang
Journal:  J Neurosci       Date:  1999-04-15       Impact factor: 6.167

Review 2.  Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias.

Authors:  R C Dodel; K Berger; W H Oertel
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

3.  Modeling the short- and long-duration responses to exogenous levodopa and to endogenous levodopa production in Parkinson's disease.

Authors:  Phylinda L S Chan; John G Nutt; Nicholas H G Holford
Journal:  J Pharmacokinet Pharmacodyn       Date:  2004-06       Impact factor: 2.745

4.  Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease.

Authors:  Phylinda L S Chan; John G Nutt; Nicholas H G Holford
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

5.  Pharmacokinetic and pharmacodynamic changes during the first four years of levodopa treatment in Parkinson's disease.

Authors:  Phylinda L S Chan; John G Nutt; Nicholas H G Holford
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

6.  Disease progression, drug action and Parkinson's disease: why time cannot be ignored.

Authors:  Nick Holford; John G Nutt
Journal:  Eur J Clin Pharmacol       Date:  2007-12-19       Impact factor: 2.953

7.  Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.

Authors:  C Colosimo; M Merello; A J Hughes; K Sieradzan; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-06       Impact factor: 10.154

Review 8.  Dyskinesias and levodopa therapy: why wait?

Authors:  Michele Matarazzo; Alexandra Perez-Soriano; A Jon Stoessl
Journal:  J Neural Transm (Vienna)       Date:  2018-02-10       Impact factor: 3.575

Review 9.  The role of neuroplasticity in dopaminergic therapy for Parkinson disease.

Authors:  Xiaoxi Zhuang; Pietro Mazzoni; Un Jung Kang
Journal:  Nat Rev Neurol       Date:  2013-04-16       Impact factor: 42.937

10.  High-frequency stimulation of the subthalamic nucleus prolongs the increase in striatal dopamine induced by acute l-3,4-dihydroxyphenylalanine in dopaminergic denervated rats.

Authors:  Emilie Lacombe; Carole Carcenac; Sabrina Boulet; Claude Feuerstein; Anne Bertrand; Annie Poupard; Marc Savasta
Journal:  Eur J Neurosci       Date:  2007-09-06       Impact factor: 3.386

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.